U.S. Markets open in 1 hr 55 mins
  • S&P Futures

    4,544.00
    +19.75 (+0.44%)
     
  • Dow Futures

    35,047.00
    +137.00 (+0.39%)
     
  • Nasdaq Futures

    15,146.25
    +112.75 (+0.75%)
     
  • Russell 2000 Futures

    2,068.10
    +8.90 (+0.43%)
     
  • Crude Oil

    86.61
    -0.35 (-0.40%)
     
  • Gold

    1,836.70
    -6.50 (-0.35%)
     
  • Silver

    24.20
    -0.03 (-0.11%)
     
  • EUR/USD

    1.1339
    -0.0008 (-0.0680%)
     
  • 10-Yr Bond

    1.8270
    0.0000 (0.00%)
     
  • Vix

    23.09
    +0.30 (+1.32%)
     
  • GBP/USD

    1.3610
    -0.0001 (-0.0095%)
     
  • USD/JPY

    114.2910
    -0.0620 (-0.0542%)
     
  • BTC-USD

    42,016.75
    -117.57 (-0.28%)
     
  • CMC Crypto 200

    997.71
    +2.97 (+0.30%)
     
  • FTSE 100

    7,584.27
    -5.39 (-0.07%)
     
  • Nikkei 225

    27,772.93
    +305.70 (+1.11%)
     

The President of Elanco Animal Health Incorporated (NYSE:ELAN), Jeffrey Simmons, Just Bought 4.3% More Shares

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Elanco Animal Health Incorporated (NYSE:ELAN) shareholders (or potential shareholders) will be happy to see that the President, Jeffrey Simmons, recently bought a whopping US$500k worth of stock, at a price of US$29.70. There's no denying a buy of that magnitude suggests conviction in a brighter future, although we do note that proportionally it only increased their holding by 4.3%.

Check out our latest analysis for Elanco Animal Health

Elanco Animal Health Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by Independent Chairman of the Board Roy Hoover for US$811k worth of shares, at about US$32.44 per share. That means that an insider was happy to buy shares at above the current price of US$31.00. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

While Elanco Animal Health insiders bought shares during the last year, they didn't sell. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
insider-trading-volume

Elanco Animal Health is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Insiders own 0.2% of Elanco Animal Health shares, worth about US$30m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Do The Elanco Animal Health Insider Transactions Indicate?

It is good to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. When combined with notable insider ownership, these factors suggest Elanco Animal Health insiders are well aligned, and that they may think the share price is too low. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example - Elanco Animal Health has 1 warning sign we think you should be aware of.

Of course Elanco Animal Health may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.